The value of blind screening in the Anticonvulsant Screening Program

Epilepsia

Volumn 53, Issue 10, 2012, Pages 1842-1843

  French, Jacqueline ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; ETHOSUXIMIDE; FELBAMATE; FLUPIRTINE; HARKOSERIDE; PENTETRAZOLE; RETIGABINE; SUCCINIMIDE; TOPIRAMATE;

ANTICONVULSANT SCREENING PROGRAM; DRUG MANUFACTURE; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; HUMAN; MAXIMAL ELECTROSHOCK MODEL; MODEL; NEUROTRANSMISSION; NONHUMAN; NOTE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SEIZURE;

ANTICONVULSANTS; EPILEPSY; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84867185393     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2012.03683.x     Document Type: Note

References (3)

1. Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Polymeropoulos EE, Kutscher B, Löscher W, Hönack D, White HS, Wolf HH,. (1996) D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 23: 211-223.
2. Ruggero F, Smith MC,. (1989) Valproate: mechanism of action. In, Levy R, Mattson R, Meldrum B, Penry JK, Dreifuss FE, (Eds) Antiepileptic drugs. Raven Press, Ltd, New York, pp. 567-575.
3. Shorvon SD,. (2009) Drug treatment of epilepsy in the century of the ILAE: the first 50 years, 1909-1958. Epilepsia 50 (Suppl. 3): 69-92.